Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Trials
- 0
- Subs
- 0
- People
- 0
- Links
- 0
Executive Summary
AI synthesisShanghai Yinnuo Pharmaceutical Technology Co., Ltd. is a Chinese biotech with extremely limited public information, presenting significant due diligence challenges for US BD teams. The company maintains clear BIOSECURE status with no designated restrictions, but the lack of disclosed management, pipeline, or corporate structure data suggests either early-stage operations or limited transparency. BD teams should approach with caution given the information opacity and prioritize comprehensive due diligence before engagement.
Structure: Corporate structure details are not publicly available, requiring direct inquiry to determine holding company arrangements, VIE structures, or subsidiary relationships. The absence of disclosed organizational information represents a significant due diligence gap that must be addressed early in any deal evaluation process.
BIOSECURE Risk
Company shows clear BIOSECURE status with no BCC designation, indicating minimal current regulatory restrictions
Key Exposures:
- •Potential future designation risk due to limited transparency
- •Unknown government relationships or funding sources
Mitigation: No public mitigation efforts identified; status unknown due to limited disclosure
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in public records
Approach: Conduct preliminary information gathering through intermediaries before direct engagement; prioritize management presentations and pipeline disclosure
Red Flags
- ⚠Complete lack of disclosed management team
- ⚠No public pipeline or technology information
- ⚠Absence of corporate structure transparency
- ⚠Limited online presence or company information
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.